General surgery in haemophiliac patients

Elias Bastounis, Emmanouil Pikoulis, Ari Leppäniemi, Dimitrios Alexiou, Christos Tsigris, Andreas Tsetis

Abstract
With improvements in medical technology, more and larger surgical procedures are performed in haemophiliac patients, but rarely reported in the surgical literature. A retrospective study from a 10 year period from one referral centre identified a total of 68 operations performed in haemophiliac patients. The levels of the defective factors were carefully monitored preoperatively and postoperatively, and replaced according to a standard formula. Special caution was taken to avoid any postoperative medication or procedures that could provoke haemorrhagic complications.

Two patients suffered postoperative bleeding complications that were managed conservatively. Inhibitory factors were detected preoperatively in one case, and postoperatively in another, and were managed with aggressive replacement therapy. There was no mortality, and the overall morbidity rate was 6%.

With adequate preoperative and postoperative monitoring of the clotting factors, meticulous haemostasis during surgery, careful postoperative nursing, and timely replacement therapy, haemophiliac patients can be operated with good results. Postoperative bleeding complications are rare, and usually amenable to conservative management.

Keywords: surgery; haemophilia; factor VIII concentrates; von Willebrand's disease

A better understanding of the clotting mechanisms and the ability to manufacture factor concentrates have enabled more and larger surgical procedures to be performed in haemophiliac patients. This study reviews the experience of surgical treatment of haemophiliac patients managed in one referral hospital with special experience in haematological problems.

Patients and methods
During a 10 year period, from 1985 to 1994, a total of 65 haemophiliac patients underwent surgical treatment in the 1st Surgical Department of the University of Athens. Their mean (range) age was 42 (8–72) years, and 62 (95%) were male. Three patients were operated twice (range) and the dose required was calculated using the following formula: weight (kg) × desired factor level (%) × 0.5. Twenty minutes after replacement therapy, the factor level was rechecked, and additional doses of the missing factor were given intraoperatively, as needed.

At operation, the aim was to achieve meticulous haemostasis using ligation for all visible bleeding and cautery only for capillary bleeding, and also trying to keep the operative time to a minimum. Creation of closed spaces was avoided and pressure bandages were used in patients with soft tissue injuries.

Postoperatively, replacement therapy was continued every eight hours for haemophilia A, and every 12 hours for haemophilia B, with daily blood measurements to maintain the factor level above 30% for 2–3 weeks. The interval and dose of the postoperative replacement therapy were similar in patients undergoing major or minor surgery for the first three days but the interval was longer, the dose smaller, and the duration shorter in the latter group during subsequent days. Analgesic drugs affecting the clotting mechanism and unnecessary...
General surgery in haemophiliac patients

495

haemophilia is the development of antibodies with the use of cryoprecipitate.2

After the introduction of the use of part I of plasma (fraction I) in 1960, the mortality rates went only emergency surgical treatment and after supplying the missing factor. Sutures were removed after 2–3 weeks, and always after factor replacement.

Results

Four patients had postoperative complications. The first patient underwent a cholecystectomy complicated by intraoperative haemorrhage from the gall bladder bed which continued for 12 days. Blood and fresh frozen plasma were given intraoperatively and postoperatively combined with factor replacement therapy, and the patient was discharged, although he had to be reoperated on three years later for obstructive common bile duct stone in another hospital.

The second patient developed a haematoma after wound excision for soft tissue injury and was treated successfully non-operatively with blood transfusions and replacement therapy.

The third patient who had undergone subtotal gastrectomy two years before for gastric haemorrhage underwent a total gastrectomy for Zollinger-Ellison syndrome, and developed a postoperative subphrenic abscess managed successfully with percutaneous drainage.

The fourth patient underwent a successful cholecystectomy and was discovered postoperatively to have an inhibitor to factor VIII, which was managed with additional replacement therapy using aPCC (Autoplex) with no further complications. In addition, in one patient an inhibitor to factor VIII was detected preoperatively and managed successfully by inducing supranormal levels of clotting factors with aggressive replacement therapy.

Discussion

Until the 1960s, haemophilia patients underwent only emergency surgical treatment and there were high mortality rates of 25%–50%.1 After the introduction of the use of part I of plasma (fraction I) in 1960, the mortality decreased below 10%, and further below 2% with the use of cryoprecipitate.3 After the development of a highly active factor VIII and IX concentrates, the mortality rate fell below 1%, and enabled the scheduling of increasingly complex elective cardiovascular and neurosurgical procedures.1

In haemophilic patients, the reported postoperative bleeding complication rate is 3%–6%, and the postoperative infection rate about 1%, confirmed also in this study.

One of the complications in patients with haemophilia is the development of antibodies or inhibitors, which have been demonstrated in 8%–20% of patients with severe haemophilia A and in 2.5%–16% of patients with severe haemophilia B.5,6 Inhibitors develop usually at an early age after few infusions of factor VIII or factor IX, and the treatment of these patients aims at controlling episodes of severe acute bleeding, preparing patients for essential surgery, and to induce immune tolerance by elimination of the antibodies.6 In our study, only one patient produced inhibitory factors postoperatively, and was managed successfully with additional replacement therapy. In one of our patients with history of gastric bleeding, high levels of inhibitor factor VIII were detected preoperatively and managed successfully with augmented replacement therapy. In general, if the patient has an inhibitor to factor VIII or IX, we have used either FVIII porcine or aPCC (Autoplex), although during the last two years in patients with inhibitors as well as in patients with acquired hemophilia, we have used recombinant FVIIa with very encouraging results. However, in cases where the risk of bleeding is clearly increased, the postponement of the elective procedure has been suggested.7 Postoperative thrombophlebitis has been reported in the literature,1 but was not detected in this series. In addition, there were no cases of allergic reactions to the infused factor, or haemolytic reactions caused by antihuman antibodies.

Learning points

- Adequate preoperative and postoperative monitoring of the clotting factors.
- Meticulous haemostasis during surgery.
- Careful postoperative nursing.
- Timely replacement therapy.

References

General surgery in haemophiliac patients

Elias Bastounis, Emmanouil Pikoulis, Ari Leppäniemi, Dimitrios Alexiou, Christos Tsigris and Andreas Tsetis

Postgrad Med J 2000 76: 494-495
doi: 10.1136/pmj.76.898.494

Updated information and services can be found at:
http://pmj.bmj.com/content/76/898/494

These include:

References
This article cites 6 articles, 0 of which you can access for free at:
http://pmj.bmj.com/content/76/898/494#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Epidemiology (401)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/